WeVote
Log In

Bill

Bill

A 4677

Requires insurance coverage for lactation consultant services

2025 Regular Session Introduced by Chantel Jackson and 3 co-sponsors

Raises tobacco-tax funding for cancer research to $10 million annually and creates a non-lapsing Cancer Research Fund to permanently support NJCCR grants and contracts.

REFERRED TO RULES
0
WeVote Research Nonpartisan
Bill Summary · A 4677

Note on bill content
- The header title you provided ("Requires insurance coverage for lactation consultant services") does not match the text of A4677/A (included below). The enacted/introduced text for A4677/A in your packet concerns the New Jersey State Commission on Cancer Research and the creation of a non‑lapsing Cancer Research Fund. This summary describes the cancer research bill text (A4677/A).

Bill at a glance

  • Bill number: A4677 (A4677A)
  • Subject: Increases tobacco‑tax funding for New Jersey State Commission on Cancer Research (NJCCR) and establishes a dedicated, non‑lapsing Cancer Research Fund in the Treasury
  • Introduced: June 28, 2024
  • Sponsors: Assemblywoman Chantel Jackson (primary); cosponsors Grace Lee, Stefani Zinerman, David Weprin
  • Status (most recent): Passed Assembly (June 9, 2025); delivered to Senate and referred to Senate Rules
  • Effective date: Immediately upon enactment

Main purpose / intent

  • To provide stable, increased, and protected funding for cancer research in New Jersey by:
    • Raising the statutory tobacco‑tax allocation to the NJCCR from $1,000,000 to $10,000,000 annually; and
    • Creating a non‑lapsing, revolving Cancer Research Fund in the Department of the Treasury to hold and disburse those monies (and any other approved funds) exclusively for commission‑authorized cancer research grants and contracts.

Key provisions

  1. Increase in statutory allocation

    • Amends section 5 of P.L.1982, c.40 (C.54:40A‑37.1) to change the annual deposit of tax collected under section 301 of P.L.1948, c.65 (C.54:40A‑8) from $1,000,000 to $10,000,000.
    • Requires that at least $5,000,000 of the fund be used for general cancer research and at least $5,000,000 for pediatric cancer research.

  2. Creation of Cancer Research Fund

    • Establishes a non‑lapsing, revolving Cancer Research Fund in the Department of the Treasury as the repository for the allocated tobacco‑tax monies and any other funds approved by the Department of Health or NJCCR.
    • Moneys and any interest earned shall be used exclusively for grants and contracts for cancer research projects authorized and approved by the commission.

  3. Administration and investment

    • State Treasurer is custodian of the fund.
    • Disbursements made by the Treasurer upon vouchers signed by the NJCCR chair or designee.
    • Funds to be invested/reinvested by the Director of the Division of Investment consistent with other State trust funds; interest credited to the fund.

  4. Repeal

    • Repeals section 8 of P.L.1983, c.6 (C.52:9U‑8) (as specified in the introduced version).

Who is affected

  • New Jersey State Commission on Cancer Research: receives a larger, dedicated stream of funding and a permanent fund to manage grants and contracts.
  • Researchers and institutions: greater and more stable grant opportunities, including a guaranteed pediatric research allocation.
  • State budget: reallocates $9,000,000 annually (statutorily) from tobacco‑tax revenue to the non‑lapsing fund (from $1M to $10M). How this affects other budget items depends on broader State appropriations and prior practice of lapsing transfers.

Potential impacts

  • Stabilizes and protects cancer research funding by preventing lapsing/transfers to the General Fund and by making funds non‑lapsing.
  • Increases capacity for both general and pediatric cancer research grants; may support initiatives to reduce disparities and expand clinical trial access (as stated in the bill’s legislative statement).
  • Fiscal implications for state budgeting processes — shifts and secures a larger dedicated portion of tobacco‑tax revenue to cancer research.

Legislative progress / next steps

  • Introduced in Assembly (6/28/2024); referred to Assembly Health, later to Insurance and Rules.
  • Reported and passed the Assembly (6/9/2025); delivered to the Senate and referred to Senate Rules (awaiting Senate action). Companion: S664 (and others from prior sessions).

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.